Numbers

The Numbers

DAQO trades at $19.22 — roughly 0.29x book value — because the market sees a commodity producer with negative margins, massive industry overcapacity, and uncertain policy rescue. The stock price is almost entirely a function of the $29/share in net cash; the operating business is being valued near zero. The single metric that would rerate this stock is gross margin turning positive on a sustained basis, which requires polysilicon ASP rising above ~$7/kg or utilization climbing past 80%.

Current Price

$19.22

Market Cap ($M)

$1,297

Book Value / Share

$65.43

Net Cash / Share

$29.50

Revenue and Earnings Power

Loading...

Revenue collapsed 86% from peak ($4.6B in FY2022) to $665M in FY2025 — driven entirely by polysilicon price, not volume. The company went from $1.8B net income to a $171M loss in three years, illustrating why commodity producers should never be valued on peak earnings.

Loading...
Loading...

Q3-Q4 FY2025 showed green shoots — gross margins turned slightly positive (4% and 7%) as costs fell and ASP stabilized. Q1 FY2026 then collapsed to $27M revenue as DAQO deliberately withheld sales volume, waiting for government price guidance.

Cash Generation — Are the Earnings Real?

Loading...

In profitable years (2020-2023), operating cash flow consistently exceeded net income — healthy conversion. FY2022 stands out: $2.5B operating CF on $1.8B net income, reflecting massive working capital inflows as receivables were collected. FY2025 showed a critical inflection: operating cash flow turned positive ($50M) even as the company reported a $171M net loss — driven by non-cash depreciation ($240M) and SBC ($56M) exceeding the loss.

Loading...

Cumulative capex from 2021-2025 totaled $3.3B — primarily building the Inner Mongolia facility. That investment cycle is now winding down (FY2026 capex guided at $100-150M), meaning FCF should improve sharply even at current depressed revenue levels.

Capital Allocation

Loading...

DAQO returned $616M through buybacks in FY2022-2024, reducing shares from 78M to 67M ADS (14% reduction). No dividends have ever been paid. SBC is significant — $56M in FY2025 on $665M revenue (8.4% of sales) — diluting the buyback benefit. The company has suspended buybacks during the downturn, preserving cash.

Balance Sheet Health

Loading...

Current Ratio

5.37

Debt / Equity

0.00

Net Cash ($M)

$1,942

Book Equity ($M)

$5,916

The balance sheet is the single strongest aspect of this company. Zero debt since FY2021. Current ratio of 5.4x. Net cash of $1.9B represents 150% of market cap. Even if the company burned $50M/quarter indefinitely, the cash runway exceeds 9 years. This balance sheet is the reason DAQO can play the attrition game.

Valuation — Historical Context

Loading...

P/B ratio is the only meaningful valuation metric when earnings are negative. At 0.45x book, DAQO trades at a fraction of book value — implying the market expects significant book value destruction ahead (asset impairments, continued losses) or doubts the realizable value of Chinese-domiciled assets.

P/B (Current)

0.45

P/B (5Y Median)

1.39

P/B (Trough - FY2024)

0.30

Per-Share Economics

Loading...

Book value per share has been remarkably stable at $63-66 through FY2023-2025 despite two years of losses — reflecting the large accumulated equity base from the boom years. The 14% share count reduction from buybacks partially offset losses.

Peer Comparison

No Results

DAQO's key peer advantage: zero debt and $1.9B net cash. GCL and Tongwei carry significant debt into the downturn. Wacker and OCI remain profitable because they serve non-Chinese markets with tariff protection and semiconductor demand. The P/B discount to Wacker (0.45x vs 1.5x) reflects both China risk and the loss-making status.

Fair Value and Scenario Analysis

No Results

Analyst consensus target is ~$25 (range $14-$41), reflecting deep uncertainty. The bear-to-bull range is 3.7x, unusually wide, because outcomes are almost entirely policy-dependent rather than operationally driven.

The numbers confirm DAQO's fortress balance sheet and cost leadership — the two attributes that matter most in a commodity trough. What the numbers contradict is any narrative of imminent recovery: Q1 FY2026 revenue of $27M (annualized run rate of ~$107M against $665M trailing) shows the business is still deteriorating operationally even as Q4 FY2025 flashed early recovery signals. Watch quarterly gross margin: if it sustains positive territory for two consecutive quarters at utilization above 60%, the stock rerates sharply — every 10 percentage points of gross margin improvement at normalized volume adds roughly $5/share in annual earnings power.